CA2198316A1 - Treatment of septic shock with anti-tnf antibodies - Google Patents
Treatment of septic shock with anti-tnf antibodiesInfo
- Publication number
- CA2198316A1 CA2198316A1 CA002198316A CA2198316A CA2198316A1 CA 2198316 A1 CA2198316 A1 CA 2198316A1 CA 002198316 A CA002198316 A CA 002198316A CA 2198316 A CA2198316 A CA 2198316A CA 2198316 A1 CA2198316 A1 CA 2198316A1
- Authority
- CA
- Canada
- Prior art keywords
- shock
- septic shock
- tnf
- mammal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010040070 Septic Shock Diseases 0.000 title claims abstract description 41
- 230000036303 septic shock Effects 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title description 4
- 230000035939 shock Effects 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract 6
- 241000282887 Suidae Species 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 50
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 50
- 241000282898 Sus scrofa Species 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000036543 hypotension Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000581444 Clinidae Species 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000736839 Chara Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60902296A | 1996-02-29 | 1996-02-29 | |
| US08/609,022 | 1996-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2198316A1 true CA2198316A1 (en) | 1997-08-29 |
Family
ID=24439040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002198316A Abandoned CA2198316A1 (en) | 1996-02-29 | 1997-02-24 | Treatment of septic shock with anti-tnf antibodies |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0791360A3 (enExample) |
| JP (1) | JPH1025251A (enExample) |
| AU (1) | AU1487597A (enExample) |
| CA (1) | CA2198316A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10022113A1 (de) | 2000-05-06 | 2001-11-15 | Daimler Chrysler Ag | Hybridantrieb für Kraftfahrzeuge |
| US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| US20130165399A1 (en) | 2010-06-18 | 2013-06-27 | Hayashibara Co., Ltd. | Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8806339D0 (en) * | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
-
1997
- 1997-02-19 EP EP97102619A patent/EP0791360A3/en not_active Withdrawn
- 1997-02-24 CA CA002198316A patent/CA2198316A1/en not_active Abandoned
- 1997-02-24 AU AU14875/97A patent/AU1487597A/en not_active Abandoned
- 1997-02-24 JP JP9054254A patent/JPH1025251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1025251A (ja) | 1998-01-27 |
| EP0791360A3 (en) | 1997-09-24 |
| AU1487597A (en) | 1997-09-04 |
| EP0791360A2 (en) | 1997-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suffredini et al. | Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. | |
| CA2208673C (en) | Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin | |
| AU715338B2 (en) | Methods for treatment of allergic asthma | |
| Bahrami et al. | Significance of TNF in hemorrhage-related hemodynamic alterations, organ injury, and mortality in rats | |
| RU2477727C2 (ru) | ПОЛИПЕПТИД, СЕЛЕКТИВНЫЙ ПО ОТНОШЕНИЮ К ИНТЕГРИНУ αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОДИРУЮЩИЙ ЕГО ПОЛИНУКЛЕОТИД, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДАННЫЙ ПОЛИПЕПТИД, И СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ | |
| CA1275951C (en) | Lysing or blocking unwanted cells | |
| US5336489A (en) | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins | |
| US5620687A (en) | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors | |
| MXPA98000760A (en) | Methods for the treatment of asthma allergy | |
| JPH02234693A (ja) | 炎症反応の調節方法 | |
| US20090087426A1 (en) | Methods for Treatment of Allergic Asthma | |
| Casas et al. | Reconstituted high-density lipoprotein reduces LPS-stimulated TNFα | |
| JP2002523379A (ja) | 抗血栓薬およびヒト化抗フォンビルブランド因子モノクローナル抗体 | |
| Espat et al. | PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock | |
| CA2198316A1 (en) | Treatment of septic shock with anti-tnf antibodies | |
| EP0868197B1 (en) | Anti-l-selectin antibodies for prevention of multiple organ failure and acute organ damage | |
| Awazu et al. | Role of endogenous atrial natriuretic peptide in congestive heart failure | |
| Ensinck et al. | Endogenous somatostatin-28 modulates postprandial insulin secretion. Immunoneutralization studies in baboons. | |
| US7537757B2 (en) | Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II | |
| JPS63263094A (ja) | モノクローナル抗体 | |
| Skarlatos et al. | Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen but not brain, in vivo in mice | |
| CA2161349A1 (en) | Immunoglobulin infusion in xenotransplantation | |
| OKANO et al. | Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock | |
| Carpenter | Manipulation of T-Cell Populations to Abrogate Allograft Rejection | |
| US20040191253A1 (en) | Inhibition of intimal hyperplasia using antibodies to PDGF receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |